Atorvastatin과 Telmisartan의 약물상호작용
Drug-drug Interactions between Atorvastatin and Telmisartan
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Atorvastatin, a HMG-CoA reductase inhibitor is widely prescribed in hyperlipidemic patients and telmisartan,an angiotensin receptor blocker is frequently used in the treatment of hypertension. Both drugs are substrates of organicanion transporting polypeptide (OATP) expressed in basolateral membrane in the liver, and undergo high first passmetabolism. Therefore, OATP-mediated hepatic uptake is important for disposition and metabolism of these drugs. Thepresent study was designed to investigate the pharmacokinetic interactions between atorvastatin and telmisartan in rats. Method: Young adult SD rats were divided into three groups (n=6, each) and atorvastatin (10 mg/kg) and telmisartan(4 mg/kg) were orally given alone and together. Heparinized blood was serially taken and plasma concentrations of bothdrugs were measured using HPLC-MS/MS. Pharmacokinetic parameters of two drugs were calculated. Results: No significantpharmacokinetic change was found except a delay of time to peak of telmisartan when administered with atorvastatin. Each drug at the present dosage seemed to be insufficient to alter the pharmacokinetic parameters of itscounterpart drug. Conclusion: Conclusively, co-administration of atorvastatin and telmisartan may lead to negligibleclinical consequences.
Abstract
Purpose: Atorvastatin, a HMG-CoA reductase inhibitor is widely prescribed in hyperlipidemic patients and telmisartan,an angiotensin receptor blocker is frequently used in the treatment of hypertension. Both drugs are substrates of organicanion transporting polypeptide (OATP) expressed in basolateral membrane in the liver, and undergo high first passmetabolism. Therefore, OATP-mediated hepatic uptake is important for disposition and metabolism of these drugs. Thepresent study was designed to investigate the pharmacokinetic interactions between atorvastatin and telmisartan in rats. Method: Young adult SD rats were divided into three groups (n=6, each) and atorvastatin (10 mg/kg) and telmisartan(4 mg/kg) were orally given alone and together. Heparinized blood was serially taken and plasma concentrations of bothdrugs were measured using HPLC-MS/MS. Pharmacokinetic parameters of two drugs were calculated. Results: No significantpharmacokinetic change was found except a delay of time to peak of telmisartan when administered with atorvastatin. Each drug at the present dosage seemed to be insufficient to alter the pharmacokinetic parameters of itscounterpart drug. Conclusion: Conclusively, co-administration of atorvastatin and telmisartan may lead to negligibleclinical consequences.
참고문헌 (26)
- Stangier J, "Pharmacokinetics of Orally and Intravenously Administered Telmisartan in Healthy Young and Elderly Volunteers and in Hypertensive Patients", J int Med Res, 28, pp.149~167 (2000)
- Wienen W, "A Review on Telmisartan: A Novel, Long-Acting Angiotensin IIReceptor Antagonist", Cardiovasc Drug Rev, 18, pp.127~154 (2000)
- Ren S, "Discovery and Characterization of Novel, Potent, and Selective Cytochrome P450 2J2 Inhibitors", Drug Metab Dispos, 41, pp.60~71 (2013)
- telmisartan in healthy volunteers, "J Clin Pharmacol", 2000, 1312~1322
- Lennerns H, "Clinical pharmacokinetics of atorvastatin", Clin Pharmacokinet, 42, pp.1141~1160 (2003)
- Kearney AS, "The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981", Pharm Res, 10, pp.1461~1465 (1993)
- Grube M, "Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart", Clin Pharmacol Ther, 80, pp.607~620 (2006)
- Kalliokoski A, "Impact of OATP transporters on pharmacokinetics", Br J Pharmacol, 158, pp.693~705 (2009)
- Ishiguro N, "Predominant contribution of OATP1b3 to the hepatic uptake of telmisartan, An angiotensin II receptor antagonist, in humans", Drug Metab Dispos, 34, pp.1109~1115 (2006)
- Macwan JS, "Development and validation of a sensitive, simple, and rapid method for simultaneous quantitation of atorvastatin and its acid and lactone metabolites by liquid chromatography-tandem mass spectrometry(LC-MS", MS), 2011, pp.400, 423~433
- Herv F, "Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding", Clin Pharmacokinet, 26, pp.44~58 (1944)
- Vats R, "Effect of multidose cilostazol on pharmacokinetic and lipid profile of atorvastatin in male Wistar rats", J Pharm Pharmacol, 64, pp.1638~1645 (2012)
- Karlgren M, "Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug-Drug Interactions", J Med Chem, 55, pp.4740~4763 (2012)
- Lins RL, "Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients", Nephrol Dial Transplant, 18, pp.967~976 (2003)
- Lau YY, "Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism", Drug Metab Dispos, 34, pp.1175~1181 (2006)
- DeGorter MK, "Interaction of three regiospecific amino acid residues is required for OATP1B1 gain of OATP1B3 substrate specificity", Mol Pharm, 9, pp.986~995 (2012)
- Kalliokoski A, "Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism", Clin Pharmacol Ther, 84, pp.488~496 (2008)
- Hermann M, "Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients", Clin Pharmacol Ther, 76, pp.388~391 (2004)
- Lemahieu WP, "Combined therapy with atorvastatin and calcineurin inhibitors : no interactions with tacrolimus", Am J Transplant, 5, pp.2236~2243 (2005)
- Backman JT, "Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites", Clin Pharmacol Ther, 78, pp.154~167 (2005)
- Lau YY, "effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers", Clin Pharmacol Ther, 81, pp.194~204 (2007)
- 윤현옥, "Drug Interaction of Warfarin with Simvastatin", Gemfibrozil : high levels of ALT, 한국임상약학회지, pp.2011, 21(3)[DOI]
- 채민경, "지역약국 방문 성인의 일반의약품 복용실태 및 일반의약품과 처방의약품과의 상호작용 연구", 한국임상약학회지, 23(1), pp.49~56 (2013), 한국임상약학회
- Miura M, "Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients", J Clin Pharm Ther, 34, pp.683~692 (2009)
- Kataoka M, "Dynamic analysis of GI absorption and hepatic distribution processes of telmisartan in rats using positron emission tomography", Pharm Res, 29, pp.2419~2431 (2012)
- Hao K, "Pharmacokineticpharmacodynamic modeling of telmisartan using an indirect response model in spontaneously hypertensive rats", Acta Pharmacol Sin, 28, pp.738~748 (2007)